What is Big Think?  

We are Big Idea Hunters…

We live in a time of information abundance, which far too many of us see as information overload. With the sum total of human knowledge, past and present, at our fingertips, we’re faced with a crisis of attention: which ideas should we engage with, and why? Big Think is an evolving roadmap to the best thinking on the planet — the ideas that can help you think flexibly and act decisively in a multivariate world.

A word about Big Ideas and Themes — The architecture of Big Think

Big ideas are lenses for envisioning the future. Every article and video on bigthink.com and on our learning platforms is based on an emerging “big idea” that is significant, widely relevant, and actionable. We’re sifting the noise for the questions and insights that have the power to change all of our lives, for decades to come. For example, reverse-engineering is a big idea in that the concept is increasingly useful across multiple disciplines, from education to nanotechnology.

Themes are the seven broad umbrellas under which we organize the hundreds of big ideas that populate Big Think. They include New World Order, Earth and Beyond, 21st Century Living, Going Mental, Extreme Biology, Power and Influence, and Inventing the Future.

Big Think Features:

12,000+ Expert Videos

1

Browse videos featuring experts across a wide range of disciplines, from personal health to business leadership to neuroscience.

Watch videos

World Renowned Bloggers

2

Big Think’s contributors offer expert analysis of the big ideas behind the news.

Go to blogs

Big Think Edge

3

Big Think’s Edge learning platform for career mentorship and professional development provides engaging and actionable courses delivered by the people who are shaping our future.

Find out more
Close

Signals Are All Around You

February 14, 2011, 12:00 AM
Lighthouse

"Effective signals in a marketplace have the characteristic that the people with a high quality product have lower costs of emitting the signal than people with a low quality product, explains Nobel Laureate economist Michael Spence. "So when the equilibrium sets up in the marketplace, the high quality people will send the signal that they're high quality and the low quality ones won’t do it."

Spence's classic example is how qualified workers can signal their worth in the job market. The basic premise is that there is an information asymmetry during hiring—employers can't sufficiently determine a worker's productivity by the interview alone. But by going to college, a worker can signal his productivity to employers. Only someone with a high quality product (his own intelligence and productivity) would subject himself to the rigors of college; if he has a low quality product, the relative cost (money and effort) would be too high to justify enrolling in college. Thus, the education is less important for what particular knowledge that worker might have learned and more important as a signal of his inherent worth.

Consider economist George Akerloff's example of a scenario in which no signaling occurs: "If you can’t distinguish between two cars of differing quality on the buying side, they all get lumped together and they’re viewed as a lottery," says Spence. "In the used car market, if there are no credible signals when you buy a car, some of them will be well-looked after, some of them will be lemons, and a lot of stuff in between, you’re just buying a lottery; you don’t really have a cost-effective way of knowing." In this market, the average price of all of the cars would naturally arrive at an equilibrium point well below the value of the good cars. And as a result, the owners of the good cars would choose not the sell their cars in this market, thereby driving all quality out of this market. All that would remain are the lemons. 

The same thing occurs in the pharmaceutical industry argues Donald Light, a professor of comparative health policy at the University of Medicine and Dentistry of New Jersey. Leaving drug testing in the hands of pharmaceutical companies, providing firewalls of legal protection behind which information about harms or effectiveness can be hidden, and allowing a low bar ofefficacy in order for a new drug to be approved all contribute to making this a market for lemons, says Light. His recent study estimates that 85 percent of all new drugs have little or no benefit, while potentially causing adverse side effects. But because Big Pharma possesses all the information in this market, it can get away with duping the public, he argues. 

More Resources: 

Michael Spence's Nobel Prize lecture on signaling

 

Signals Are All Around You

Newsletter: Share: